NASDAQ:MNLO - Menlo Therapeutics Stock Price, News, & Analysis

$6.10
-0.14 (-2.24 %)
(As of 06/24/2019 04:00 PM ET)
Today's Range
$6.10
Now: $6.10
$6.39
50-Day Range
$6.05
MA: $6.59
$7.08
52-Week Range
$3.74
Now: $6.10
$12.00
Volume27,428 shs
Average Volume73,136 shs
Market Capitalization$146.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.95
Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNLO
CUSIPN/A
Phone650-486-1416

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.64 million
Book Value$5.61 per share

Profitability

Net Income$-51,440,000.00

Miscellaneous

Employees43
Market Cap$146.01 million
Next Earnings Date8/7/2019 (Estimated)
OptionableNot Optionable

Receive MNLO News and Ratings via Email

Sign-up to receive the latest news and ratings for MNLO and its competitors with MarketBeat's FREE daily newsletter.

Menlo Therapeutics (NASDAQ:MNLO) Frequently Asked Questions

What is Menlo Therapeutics' stock symbol?

Menlo Therapeutics trades on the NASDAQ under the ticker symbol "MNLO."

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc (NASDAQ:MNLO) issued its quarterly earnings results on Thursday, May, 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.81) by $0.00. View Menlo Therapeutics' Earnings History.

When is Menlo Therapeutics' next earnings date?

Menlo Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Menlo Therapeutics.

What price target have analysts set for MNLO?

4 brokers have issued 1-year price objectives for Menlo Therapeutics' stock. Their forecasts range from $7.00 to $29.00. On average, they expect Menlo Therapeutics' share price to reach $20.3333 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for Menlo Therapeutics.

What is the consensus analysts' recommendation for Menlo Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Menlo Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Menlo Therapeutics.

What are Wall Street analysts saying about Menlo Therapeutics stock?

Here are some recent quotes from research analysts about Menlo Therapeutics stock:
  • 1. According to Zacks Investment Research, "Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California. " (6/20/2019)
  • 2. Cantor Fitzgerald analysts commented, ". After a solid quarter of execution in 1Q19, we reiterate our OW rating and 12-month price target of $25 for MNLO shares. We continue to believe that upward earnings revisions and multiple expansion will drive the stock higher. A greater appreciation for the company’s multiple indication approach for serlopitant will increase earnings estimates to levels not yet reflected in FactSet consensus expectations, in our view." (5/2/2019)

Has Menlo Therapeutics been receiving favorable news coverage?

Media coverage about MNLO stock has trended neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Menlo Therapeutics earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Menlo Therapeutics.

Who are some of Menlo Therapeutics' key competitors?

What other stocks do shareholders of Menlo Therapeutics own?

Who are Menlo Therapeutics' key executives?

Menlo Therapeutics' management team includes the folowing people:
  • Mr. Steven L. Basta, Pres, CEO & Director (Age 53)
  • Ms. Kristine M. Ball CPA, Sr. VP of Corp. Strategy & CFO (Age 47)
  • Dr. Mary C. Spellman, Chief Medical Officer (Age 57)
  • Dr. Paul S. Kwon M.D., Chief Scientific Officer (Age 48)
  • Mr. Stuart D. Sedlack M.B.A., VP of Bus. Devel. (Age 54)

When did Menlo Therapeutics IPO?

(MNLO) raised $86 million in an IPO on Thursday, January 25th 2018. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and JMP Securities was co-manager.

Who are Menlo Therapeutics' major shareholders?

Menlo Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include First Manhattan Co. (9.70%), Janus Henderson Group PLC (6.26%), JPMorgan Chase & Co. (2.71%), Alambic Investment Management L.P. (0.28%), Spark Investment Management LLC (0.22%) and Acadian Asset Management LLC (0.18%). Company insiders that own Menlo Therapeutics stock include Presidio Partners 2007 Gp, LP and Vivo Capital Surplus Fund Viii. View Institutional Ownership Trends for Menlo Therapeutics.

Which major investors are selling Menlo Therapeutics stock?

MNLO stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Alambic Investment Management L.P. and JPMorgan Chase & Co.. View Insider Buying and Selling for Menlo Therapeutics.

Which major investors are buying Menlo Therapeutics stock?

MNLO stock was bought by a variety of institutional investors in the last quarter, including First Manhattan Co., Acadian Asset Management LLC and Spark Investment Management LLC. View Insider Buying and Selling for Menlo Therapeutics.

How do I buy shares of Menlo Therapeutics?

Shares of MNLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Menlo Therapeutics' stock price today?

One share of MNLO stock can currently be purchased for approximately $6.10.

How big of a company is Menlo Therapeutics?

Menlo Therapeutics has a market capitalization of $146.01 million and generates $10.64 million in revenue each year. The company earns $-51,440,000.00 in net income (profit) each year or ($2.37) on an earnings per share basis. Menlo Therapeutics employs 43 workers across the globe.View Additional Information About Menlo Therapeutics.

What is Menlo Therapeutics' official website?

The official website for Menlo Therapeutics is http://www.menlotherapeutics.com/.

How can I contact Menlo Therapeutics?

Menlo Therapeutics' mailing address is 200 CARDINAL WAY 2ND FLOOR, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-486-1416 or via email at [email protected]


MarketBeat Community Rating for Menlo Therapeutics (NASDAQ MNLO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Menlo Therapeutics and other stocks. Vote "Outperform" if you believe MNLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel